Chronic sarcoidosis is a complex disease with numerous comorbid conditions and can be fatal in some cases. Recognizing causes of morbidity and mortality is important to effectively select treatments, manage symptoms and improve outcomes. The purpose of this review is to examine emerging knowledge on morbidity and mortality in sarcoidosis.
INTRODUCTION
Although many patients with sarcoidosis resolve spontaneously, a significant proportion of patients have chronic or progressive disease with resultant morbidity. A small proportion of patients die from the disease. Morbidity and mortality can be due to both the disease and its treatments. Efforts have been made to determine prognostic factors for mortality and progressive disease in order to identify patients with a protracted clinical course, although it is not clear whether earlier treatment is beneficial. Not all morbidities associated with sarcoidosis respond to immunosuppression, and understanding the underlying mechanisms may aid in better management of symptoms.
MORTALITY
Mortality rates in sarcoidosis range from less than 1 to 8% depending on the care setting, severity of disease and location, and appear to vary by age, ethnicity and sex [1] [2] [3] . A population study of death certificates in the United States (U.S.) from 1988 to 2007 shows an age and sex-adjusted mortality rate of 4.32/1 000 000, with a majority of deaths (58.8%) occurring from underlying sarcoidosis. Mortality is highest in nonHispanic blacks, women and in ages over 55 years [4] . Similar rates of 4.2/1 000 000 deaths in people with sarcoidosis are seen in England's national death certificate data in 2008, and 2.3/1 000 000 with sarcoidosis as the underlying cause [5] . In Japan, ageadjusted mortality rates in the population are 0.1-0.2 per million [6] . The Black Women's Health Study shows age-adjusted mortality at 94 deaths per 10 000 person-years, 2.44 times higher than women without sarcoidosis [7 Increasing mortality over the past decades has been suggested. Swigris et al. [4] show an increased trend over a period of years, particularly in Blacks, women and older populations. A prior study in the U.S. shows an increase in mortality from 1.3 to 1.6/ 1 000 000 in men and from 1.9 to 2.5/1 000 000 for women from 1979 to 1991 [9] . In England, mortality rate has also increased [10] . However, questions remain whether these trends are related to increasing incidence or recognition of the disease, increased severity, coding differences or reflective of an ageing sarcoidosis population. A meta-analysis of earlier mortality studies found higher mortality in Blacks to be a factor of higher incidence in the black population, arguing against a higher case-fatality rate by race or ethnicity [2] . Current studies do not address these factors directly, and further evaluation is warranted.
Post-transplantation survival for lung, heart and liver in patients with sarcoidosis is comparable to overall transplantation survival for each organ [11] . In lung transplantation, pulmonary hypertension, oxygen use and African-American race are independent predictors of mortality for sarcoidosis patients on the waiting list [12] . Although long-term survival is similar to other lung diseases, mortality does appear higher within the first year, which may be related to increased primary graft dysfunction in sarcoidosis patients [13,14,15 & ,16 & ]. Data regarding heart transplantation survival are not uniform, with some centres reporting better or worse survival [17] .
Similarly, it appears that liver transplant survival for sarcoidosis may be worse than for primary biliary cirrhosis or primary sclerosing cholangitis, but still favourable, and similar to other liver diseases [18, 19] . Firm conclusions are limited by the rarity of heart and liver transplantation for sarcoidosis.
Differences in survival may relate to the presence (or recurrence) of sarcoidosis in alternative organs, infection risk or unknown immune factors related to graft dysfunction.
MORBIDITY
On an individual level, morbidity affects quality of life and function. The presence of dyspnoea and the extent of concomitant morbidity predict anxiety and depression in sarcoidosis patients [20 & ]. In the U.S. population, hospitalizations of patients with sarcoidosis over the past 10 years have increased significantly, but do not appear to be related to the primary diagnosis of sarcoidosis [21 && ]. This rise is particularly prominent in African-Americans, women and patients over 55 years of age, implying that comorbid conditions, treatments and evolving age are contributing to increasing morbidity.
Morbidity in sarcoidosis is largely related to the affected organ system(s), with pulmonary, cardiac, hepatic, neurologic and ocular involvement often having the most severe consequences [22] . Frequency and morbidities of organ involvement are summarized in Table 1 . Multiple studies show that sarcoidosis tends to be more severe in black patients, whereas white patients are more likely to have spontaneous resolution [23, 24] . Japanese patients have a higher prevalence of cardiac and ocular disease than Western populations [8] . Last, lower socioeconomic status has been associated with more severe disease and new organ involvement [24] . The following focuses on the most recent advances in knowledge related to cardiopulmonary involvement, bone health, pain and fatigue.
Respiratory impairment
Pulmonary involvement can become symptomatic with dyspnoea or cough. It is highly prevalent and can cause decline in lung function [25] . The clinical course can be acute, subacute, chronic or progressive. Intermittent acute flares of disease (both during and after treatment), marked by decreased pulmonary function, symptoms and exclusion of other respiratory causes, have also been described [26 & ]. Flares (or 'exacerbations') may respond to low-dose corticosteroids, although there are few studies guiding diagnosis and treatment.
Pulmonary fibrosis is a risk factor for mortality. Contrary to the belief that sarcoidosis is a benign disease, a recent retrospective study from France showed that sarcoidosis patients with pulmonary fibrosis have markedly decreased survival compared with the general population. Complications include long-term need for oxygen, progressive respiratory
KEY POINTS
Mortality and morbidity appear to be increasing over the years in the population, although the reasons for this are unclear and could include increasing incidence or recognition of sarcoidosis, increased severity, or an ageing sarcoidosis population.
Understanding causes of morbidity and predictive factors for poor outcomes is important to determine appropriate management of symptoms and complications of sarcoidosis.
Older patients with sarcoidosis are more likely to have chronic sarcoidosis, comorbid conditions and side effects to treatments than younger patients, increasing the complexity of diagnosis and management in the ageing population.
failure, bronchiectasis, pulmonary hypertension, pneumothorax, aspergillomas, pulmonary embolism and infections [27] . Pathophysiologically, it is unknown whether progressive fibrosis depends on granulomatous inflammation or is a result of alternative inflammatory or fibrotic mechanisms. Furthermore, questions remain as to whether the process is early or late stage [28 && ]. Research is necessary to determine whether and when immunosuppression may alter the clinical course. Generally, it is recommended that if accompanying granulomatous inflammation is suspected, immunosuppression should be initiated to prevent further organ damage [28 && ]. Pulmonary hypertension is present in approximately 5-12% of unselected patients and up to 74% of patients awaiting lung transplantation [29] [30] [31] . Its presence has repeatedly been shown to be an independent predictor of mortality [27, 32] . Mortality or transplantation rate is reported as 41% with a median survival of 5.3 years in a meta-analysis of sarcoidosis patients with pulmonary hypertension [33 & ]. Treatment with pulmonary vasodilators may improve functional parameters and haemodynamics, but it is not clear whether it affects survival [33 & ].
The pathophysiology of pulmonary hypertension in sarcoidosis is varied and can be due to granulomatous involvement of the heart, lungs or vasculature, abnormal vaso-reactivity, porto-pulmonary hypertension or compression by lymph nodes. It is more common in patients with pulmonary fibrosis or advanced lung disease, but can be present and severe in the absence of lung disease [34, 35] . A recent study has shown that patients with an elevated pulmonary artery pressure in the absence of a high wedge pressure have an increased risk of mortality compared with those with pulmonary hypertension related to left ventricular dysfunction [32] . Patients often have progressive dyspnoea. Evaluation should be considered in patients with symptoms out of proportion to parenchymal disease, advanced lung disease, low diffusing capacity and desaturation on a a Percentage of patients with organ involvement at presentation with sarcoidosis from the ACCESS study (n ¼ 736 sarcoidosis patients) [22] . Organs without a percentage were not determined in the ACCESS study. Data from [22] .
6-min walk [36] . Because of its associated mortality risk, transplant evaluation should be considered in sarcoidosis-associated pulmonary hypertension.
Cavitary lung disease and mycetomas
Patients with chronic inflammation can develop pulmonary cavities with resultant mycetomas, most often caused by aspergillus [37,38,39 & ]. Aspergillusrelated lung disease occurs in up to 1-2% of patients and is associated with poor outcomes [40] . The presence of a mycetoma may reflect the severity of pulmonary disease. It is speculated that aspergillomas may partially result from the structural abnormalities in the lung and/or an altered immune system due to sarcoidosis or immunosuppressives. Antifungals are typically utilized, as is surgery in selected cases. Mycetoma is often a contra-indication to lung transplant due to high perioperative mortality, although in a small series of patients, perioperative antifungals and bilateral transplantation may improve outcomes in highly selected patients [41] .
Cardiac
Granulomatous inflammation of the heart can cause ventricular or atrial arrhythmias, sudden death or heart failure. Cardiac MRI and PET scans are increasingly being used to diagnose cardiac sarcoidosis with better sensitivity and specificity [42, 43] . Electrophysiology studies may also be helpful for risk stratification [44] .
Death due to cardiac reasons in sarcoidosis patients has been reported as 25% in the U.S, and higher in Japan [4, 45] . The presence of sustained ventricular tachycardia, severity of heart failure and left ventricular end-diastolic diameter predict sudden death [45] . Late-gadolinium enhancement on cardiac MRI, indicating myocardial scar, is an independent predictor of death and potentially lethal cardiac events, superior to ejection fraction, left ventricular end-diastolic volume or heart failure presentation in predicting adverse cardiac events [ 
Pain and fatigue
Pain and fatigue are becoming increasingly recognized as major comorbid conditions. Pain may reflect arthritis, myopathy (sarcoidosis or steroidinduced), small fibre neuropathy or fibromyalgia syndrome. Fatigue is present in over 80% of patients and may be the main contributor to impaired quality of life [51, 52] . The causes of fatigue are multifactorial and can include inflammation, treatments or comorbidities. Given the association between sarcoidosis and sleep disorders, a sleep study is often recommended in the work-up of fatigue [53 && ]. Sarcoidosis patients also have decreased muscle strength and exercise capacity [52, 54] . Fatigue does not respond well to immunosuppression and may actually be compounded by these medications. Exercise programmes, stimulants and behavioural therapy are currently being studied and may be beneficial in some patients [ 
Bone health
Osteoporosis and fracture risk are important complications of sarcoidosis and treatment. In one series, 20% of sarcoidosis patients had vertebral deformities that suggested fractures despite normal bone density, increasing to 32% after 4 years of follow-up with no change in bone density measurements [58] . These rates appear higher than comparable published population data. Increased markers of bone turnover suggest a potential alteration of bone remodelling, possibly related to cytokines from chronic inflammation [59] . Another study showed lower bone density in postmenopausal women with sarcoidosis compared to controls, regardless of treatment, highlighting the impact of age and sarcoidosis on bones [60] . The use of corticosteroids as treatment is also problematic and may depend both on the duration and dose [59, 61] . As for now, it is generally recommended that patients on chronic corticosteroids be strongly considered for osteoporosis prevention and treatment, and it may be prudent to assess bone health in all sarcoidosis patients on the basis of the potential bone disease associated with sarcoidosis. Further study on the role of bone density testing, biomarkers and the influence of inflammation is warranted to better guide management algorithms. It has long been debated whether there is a higher risk of cancer in sarcoidosis patients. Sarcoid-like reactions in malignancy and chemotherapy are well described, making it difficult to discern two separate entities, particularly if temporally related. A recent population-based cohort study in patients with cancer supports the premise of a higher risk of malignancy. In this study, a history of hospitalization for sarcoidosis was associated with higher incidence, worse prognosis and excess mortality for six types of cancer [65, 66] . Conversely, prior associations with cancers broach the idea that sarcoidosis is an immunologic response to a neoplasm [67, 68] . The answers to these questions are far from clear and continue to be discussed.
ASSOCIATED DISEASES
Three studies have shown a higher frequency of pulmonary embolism than the general population [69] [70] [71] . Results from decedent records may also imply pulmonary embolism as a potential contribution to mortality. The cause of increased risk is unknown, but could reflect treatment effects, associated hypercoagulable disorders, shared mechanism or a result of decline in mobility due to sarcoidosisrelated morbidities.
TREATMENT-RELATED COMORBIDITY
Treatments for sarcoidosis often include immunosuppressive medications that can have notable side effects and toxicities. All of the immunosuppressives contribute to increased susceptibility to infection [27,37,72 & ,73] . Higher use of corticosteroids has been linked to increased number of nonsarcoidosis-related emergency department visits compared with patients with lower cumulative corticosteroid exposure [73] .
There is continued controversy on whether corticosteroids may prolong the course of sarcoidosis, particularly in acute disease, limiting the benefit of early treatment in many cases [74] . Use of corticosteroids has been associated with higher mortality rates, even when accounting for stage (a proxy for severity) of disease [2] . Corticosteroid treatment has also been implicated in the development of recurrent flares [26 & ]. In theory, early use of corticosteroids may prevent natural clearance of an unknown antigen, perpetuating the granulomatous response. Conversely, earlier treatment in chronic sarcoidosis and pulmonary fibrosis may improve outcomes, highlighting the complexity of treatment decisions, and the importance of further research into prognostic indicators [27] .
AGEING AND COMORBIDITY IN SARCOIDOSIS
Although sarcoidosis is commonly thought of as a disease of the young, almost 30% of patients in the ACCESS cohort were older than 50, and epidemiologic studies report a second peak in incidence between 50 and 65 years [8, 22] . It can also be speculated that improving treatments are prolonging survival, increasing the ageing sarcoidosis population. In light of more recent evidence showing increased mortality and hospitalizations in older patients, understanding and managing comorbidity may be becoming increasingly important [ 
CONCLUSION
Mortality in sarcoidosis approximates 5% of cases and may be increasing in the overall population. Morbidity from chronic sarcoidosis can be substantial and contribute to poor outcomes. Prospective studies are needed to further understand the contribution of disease complications, treatments, ageing and comorbid conditions to long-term morbidity and mortality in sarcoidosis.
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